Chapel Hill startup with ties to UNC lands rights to drug offering hope to cystic fibrosis patients

Posted Oct 27, 2019
Path BioAnalytics (PBA), a precision medicine startup with ties to UNC, has scored the rights to a new drug therapy offering hope to cystic fibrosis (CF) patients with rare mutations. PBA is a graduate of Launch Chapel Hill, an accelerator program based in Chapel Hill, as well as the Kenan Flagler Business School program Startup UNC. (WRAL Tech Wire)

Related: Campus Connections

When Every Second Counts: This UNC Device is Saving Lives
A breakthrough from UNC is helping frontline teams fight America’s drug crisis. Chemist Mike Ramsey’s research led to the MX908, a handheld mass spectrometer, that...
Sun Feb 22, 2026

Forbes Names Carolina to “Best Large Employer” List
The University of North Carolina is the top-ranked public institution in North Carolina on the Forbes 2026 Best Large Employer List released Tuesday. UNC is...
Sat Feb 21, 2026

For Tift Merritt, Time and Patience Have Made the Difference
Tift Merritt never thought she’d end up back in her hometown of Raleigh, North Carolina. For about 15 years she toured through America and Europe...
Sun Feb 15, 2026

Rich Eisen can’t bring himself to watch Stuart Scott ’30 for 30' yet
ESPN’s latest 30 for 30 documentary stays close to home, covering the life of Stuart Scott, an icon of the Worldwide Leader’s SportsCenter era. Rich...
Sun Feb 15, 2026